NovAccess Global Inc. Overview
Pro stress-test →NovAccess Global is a biotech company accelerating research and development of novel cancer immunotherapies. The company's research is focused on the development of immunotherapeutic approaches to treating patients with Glioblastoma and other brain tumors, with additional research efforts centered on novel drug development to target cancer stem cells and other multi-resistant cancer cells. The company operates through its subsidiary StemVax Therapeutics, which is developing dendritic cell-based immunotherapies.
Strategic Profile
Pro stress-test →StemVax features a recently approved US patent (US9764014B2) in the category of "Cancer Antigens" related to the "treatment of cancer using vaccination therapy." In January 2024, NovAccess announced $10.7 million financing to establish a strong financial base to advance development of novel cancer immunotherapies. The company positions itself in an underserved market with limited existing immunotherapy treatments for brain tumors.
Competitive Landscape
Pro stress-test →Currently, there is no immunotherapy for treating brain tumor patients available in the market. NovAccess competes indirectly with conventional glioblastoma treatments (surgery, radiation, chemotherapy) and developing dendritic cell therapies from academic institutions. Larger biotech companies are exploring alternative modalities (checkpoint inhibitors, CAR-T cells) for brain tumors, though market remains underserved relative to need.
Industry Context
NovAccess Global Inc. operates in Brain tumor immunotherapy.
Key facts
Founded: 2020 · Headquarters: Chagrin Falls, Ohio, US · Employees: 2-10 · Revenue: N/A · Market cap: N/A